Microfluidic device
09849456 · 2017-12-26
Assignee
Inventors
Cpc classification
B01L2300/0627
PERFORMING OPERATIONS; TRANSPORTING
B01L2200/10
PERFORMING OPERATIONS; TRANSPORTING
B01L2300/12
PERFORMING OPERATIONS; TRANSPORTING
B01L2200/0668
PERFORMING OPERATIONS; TRANSPORTING
B01L2300/0864
PERFORMING OPERATIONS; TRANSPORTING
B01L2400/086
PERFORMING OPERATIONS; TRANSPORTING
B01L2200/0636
PERFORMING OPERATIONS; TRANSPORTING
B01L3/502761
PERFORMING OPERATIONS; TRANSPORTING
International classification
B01L3/00
PERFORMING OPERATIONS; TRANSPORTING
Abstract
Disclosed herein is a microfluidic device comprising, at least one sample inlet for receiving biological cells in a biological fluid sample; at least one sheath flow inlet for receiving a sheath fluid; at least one curvilinear channel configured to provide the biological fluid sample substantially in an outer flow and the sheath fluid in substantially an inner separated flow; a plurality of cell traps at the periphery of the curvilinear channel, each trap configured to admit a single cell having a targeted size range from the outer flow.
Claims
1. A microfluidic device comprising: at least one sample inlet for receiving biological cells in a biological fluid sample; at least one sheath flow inlet for receiving a sheath fluid; at least one curvilinear channel defining an arc region configured to provide the biological fluid sample substantially in a stable outer layer flow and the sheath fluid in substantially a stable inner layer separated flow; and a plurality of cell traps at the periphery of the arc region of the curvilinear channel, each trap configured to admit a single cell having a targeted size range from the outer layer flow.
2. The device of claim 1, further comprising an ejector configured to eject each single cell having the targeted size range from each trap during an ejection mode.
3. The device of claim 2, wherein the cell traps include a first port proximate the outer flow and configured to admit the single cell having the targeted size range and a second port distal the outer layer flow.
4. The device of claim 3, wherein the second port is configured to provide a lower pressure relative to the outer layer flow during a trapping mode.
5. The device of claim 3, wherein the second port is further configured to provide a high pressure during the ejection mode.
6. The device of claim 3, wherein the second port is selected from the group consisting of a weir, a constricted channel, an optically switched gate, and a dielectrically switched gate.
7. The device of claim 6, wherein the weir has a narrowest dimension less than 5 μm.
8. The device of claim 2, wherein the at least one sample inlet is configured to control the volume and/or flow rate of the biological fluid sample.
9. The device of claim 8, further wherein the at least one sheath inlet is configured to control the volume and/or flow rate of the sheath fluid.
10. The device of claim 9, wherein a viscosity of the sheath fluid is between 2 to 10 times, between 2 to 4 times, or approximately 3 times that of the biological fluid sample.
11. The device of claim 10, wherein the viscosity, respective volume and/or flow rates are configured to achieve an outer layer flow width of 15-25 μm.
12. The device of claim 2, which is configured to flush the channel between the trapping mode and the ejection mode.
13. The device of claim 2, wherein the device is moulded from PDMS or a hard plastic bonded onto a glass slide.
14. The device of claim 2, further comprising an optical detector configured to determine the presence of a cell within each trap and/or the type or identity of the cell within each trap.
15. The device of claim 14, wherein the optical detector is suitable for selecting a targeted cell type.
16. The device of claim 15, wherein the targeted cell type is a circulating tumour cell and/or the targeted size range is 10 μm to 30 μm.
17. The device of claim 2, further comprising a recycling port configured to recirculate the fluid sample through the channel.
18. The device of claim 2, further comprising an outlet configured to provide each ejected single cell to a predetermined location.
19. The device of claim 1, wherein the arc region extends over at least 180°.
Description
BRIEF DESCRIPTION OF THE FIGURES
(1) The invention will now be described in further detail below, with the aid of the following figures.
(2)
(3)
(4)
(5)
(6)
(7)
(8)
(9)
(10)
DETAILED DESCRIPTION
(11) A system for sorting and isolating single cells is illustrated in
(12) The system is able to sort and provide single cells in the order of thousands of cells onto a recovery substrate, which can then be immediately used in subsequent downstream analyses. The recovery substrate is an exchangeable platform capable of holding different types of media, such as a common glass slide typically used for cellular imaging or well plates (different sizes) used in PCR and cell culture. For instance, if the user is interested in identifying a subpopulation of cells within its input sample pool through immunocytochemistry or fluorescence in-situ hybridization, the cells can be immobilized onto poly-L-lysine coated slides during cell recovery and subsequently incubated with antibodies of interest for the study in question. A suitable substrate may be chosen depending on what is to be done to the cells (e.g. they type of analysis that the cells are to be subjected to). The imaging setup on the system will also be able to provide fluorescence scans to discriminate against the different cellular sub-types present. Furthermore, as the positioning of each cell is predetermined by the system, the substrate can be easily archived for future analysis if needed.
(13) A potential downstream application that will greatly benefit from the single cell sample preparation system is next generation sequencing (NGS). NGS is a growing and important application that has brought about a paradigm shift in the biomedical sciences, with a profound impact on the understanding of genetic variations, and improved clinical assessments. By choosing a suitable recovery substrate, such as a 96/384 well PCR plate, this will be directly compatible with existing platforms to perform the cell lyses and subsequent sequencing library preparations. The possibilities for prospective downstream applications benefiting from this sample preparation system are limitless and it will enhance the productivity of current detection methods by providing higher throughput.
(14) The design of a microfluidic device 100 is depicted in
(15) Such devices may be moulded from PDMS via soft lithography, hot embossing methods or injection moulding.
(16) In the depicted system, as shown in
(17) It will be appreciated that there is no limit or specific design consideration on the spacing or the curvature of the channel.
(18) In order to achieve minimal losses and high speed isolation of cells, input cells (262) are focused to the side of the channel wall (
(19) The device may be designed to capture CTCs, but may equally be designed for the isolation of any cell types, optionally excluding red blood cells and platelets. For example the dimension of the weir (264) and the chamber (260) depend on the target cell size. For a CTC of approximately 15 μm diameter, the chamber (260) should be between 16-21 μm wide (e.g. 17-20 μm), and the weir gap should be 0.5 μm to about 5 μm (e.g. 1 μm to 3 μm, such as 1.5 μm to 2.5 μm, e.g. 2 μm).
(20) In order to ensure that the cells are captured by the cell holding chambers, the flow of the sheath flow (265) and the cell flow (266) are optimized such that the cell flow stream has to be of similar width to the dimensions of the cells that have been targeted. This enables the cells in the cell flow stream to be as close to the chamber as possible. For example, when the selected cells have a size of 15 μm, the targeted width of the cell flow is in the range of 15-25 μm. Optionally, a sheath flow of higher viscosity can be used to minimize waste volume (e.g. the viscosity of the liquid used as the sheath flow may be 2 to 10 times, such as 2 to 4 times, such as 3 times that of the liquid used as the cell flow vehicle). Any suitable syringe pump may be used for the cell flow and sheath flow lines and the system may be controlled by a computer running control software.
(21) The conditions used above essentially ensure that the two flows will not mix due to the laminar characteristics of each flow. Diffusion between the separate flows is also minimized as the length of the channel is relatively short.
(22) While the vast majority of cells will remain in the biological sample fluid, or outer, flow (140), there may be some exceptions. These exceptions are larger cells whose centre of mass exceeds the focus stream dimensions of the biological sample fluid flow and will end up following the stream line of the sheath, or inner, flow (150).
(23) The sheath flow liquid may comprise any suitable cell compatible buffer. For example, the sheath flow liquid may contain a varying concentration of glycerol mixed with water/phosphate buffered saline (PBS). Other suitable sheath flows may include polyethylene glycol or dextran in varying concentrations mixed with water/PBS. It will be appreciated that the sheath flow may contain a combination of any of glycerol, polyethylene glycol and dextran at varying concentrations mixed with water/PBS.
(24) For example, during the trapping phase the flow rate may be between 100-400 μL/min with a sheath to cell flow fluid viscosity ratio of approximately 3:1. The volumetric ratio of cell to sheath flow rate (in mL per second) may be from about 1:1 to about 1:5 and the concentration of the sample may be greater than or equal to 100 cells per mL (e.g. from about 1,000 cells per mL to about 2,000,000 cells per mL, for example from about 2,000 cells per mL to about 1,000,000 cells per mL). Using these parameters, it is expected that the filling of all cell holding chambers will take from almost instantaneous filling to 30 minutes (e.g. 0.01 seconds to 10 minutes, such as 0.1 seconds to 120 seconds). It will be appreciated that the time to fill all of the chambers will vary according to the concentration of the cells in the fluid sample.
(25) In respect of CTCs, it is estimated that the concentration of such cells in a pre-enriched blood sample is typically about 1 cell in one billion blood cells. However, for an enriched sample the concentrations of CTCs may be about 1 cell in 1000-10,000 blood cells. Once the cell flow and the sheath flow have passed the hydrodynamic focusing region and the cell holding chambers, the flows are directed to a recycling port. Optionally, the recycling port is bifurcated to enable a better separation between the sheath flow and the cell flow, particularly when the sheath flow has a higher viscosity than the cell flow.
(26) After all of the chambers are full, the hydrodynamic focusing region may be flushed (e.g. with any suitable cell buffer or nuclease-free water).
(27) Then the ejection phase begins. Each cell is individually released onto the recovery substrate by applying a positive pressure to the respective cell chamber (cell ejection control in
(28) It will be appreciated that the user has the option to dispense each cell individually or any other possible combination, up to and including all of the cells trapped in the cell holding chambers. It will be further appreciated that the ejection of the cell can be varied according to the desires of the operator and may be changed for each ejection run. This flexible dispensation system allows for titration experiments to be conducted in certain studies.
(29) Another important feature of the device is the ability to recycle (lost samples) that failed to enter the cell chambers on the first (or subsequent) passes. As the system is targeted at applications where the quantity of the desired cellular samples is limiting or rare, it is vital to ensure maximum recovery of the input cellular materials. This is accomplished by routing the focused cell stream from the recycling port (220) back into the cell flow inlet (240) where the cells will get a further chance of being accepted into the cell holding chambers. The cycle of cell isolation repeats until the cellular sample input is depleted. For example, depletion of a recycled sample may be determined in an automated version of the device by setting the device to stop recycling the sample when no cells are captured over a period of 5 minutes.
(30) If optics are used to review whether all of the chambers are filled (prior to dispensing), then those optics can also be used to select the cells of interest. For example optical systems may make use of brightfield or fluorescence imaging. This allows the operator to get rid of noise or unintended cells. For example, in the depicted device, after all of the ten chambers are filled, if chamber 5 is the only chamber that has a cell of interest (the target cell) then that cell can be dispensed onto a plate/slide while the other nine cells can be dispensed simultaneously to the waste. This waste may be the recycling port or a separate waste port. Such a sample can readily be fed into any single cell analysis platform. This eliminates the need to move the slide/plate to a cell-picking station to select the cells of interest from a massively parallel plate of single cells.
(31) The depicted system can be used as an aid in sample preparation at large sequencing laboratories, or at central pathology laboratories where frequent immuno-cytochemistry, fluorescence in situ hybridization (FISH) and other molecular methods are carried out. The system can also serve cell/molecular biology laboratories, providing them with a full analysis on single cells with its integrated imaging capabilities to address cellular diversity. The depicted system has already been used to prove the concept of cell isolation and recovery with the microfluidic design, as described below.
(32) The system is a significant advance over current research endeavours on circulating tumour cell (CTC) isolation and detection that further bridges the gap between research establishments and clinical settings. With the depicted system's ability to prepare samples for downstream analysis, it enables a more sensitive measure to detect mutations and variations which are currently masked by the presence of significant amounts of white blood cells. For instance, the gold standard of mutational analysis using conventional PCR and Sanger sequencing has a limit of detection at 1% which is usually not attainable with samples with low CTC counts. The depicted system can ensure that there is sufficient sample purity before performing downstream analysis.
(33) Experimental Section
(34) Manufacture of Device
(35) Proof of concept experiments have been pursued with devices fabricated using PDMS via soft lithography (e.g. see the methods described in Qin, D., Xia, Y. & Whitesides, G. M. Soft lithography for micro- and nanoscale patterning. Nature protocols 5, 491-502 (2010) and in Whitesides, G. M., Ostuni, E., Takayama, S., Jiang, X. & Ingber, D. E. Soft lithography in biology and biochemistry Annual review of biomedical engineering 3, 335-373 (2001) incorporated herein by reference).
(36) Proof of Concept
(37)
(38) This system results in high isolation rates, when used with an optimized hydrodynamic focused cell flow and also illustrates the potential of recycling lost cells back into the system so that the total cell recovery rate can be enhanced. This system also allows the positive recovery of single beads by applying a positive pressure to the desired cell chamber and this visually verification of the retrieval was obtained by optical imaging.
(39) Optimised Sheath Flow
(40) Flow control within the device of
(41) In the current example, an NI Labview (National Instruments, USA) interface for the control of two syringe pumps that feed both the cell and sheath flow lines is used. The software provides an active regulation of the flow rates of each flow line without having to manually change the parameters on the pump each time. It also helped to synchronize the start of the pumps to minimize transient responses of the system. This software currently controls 2 syringe pumps. These syringe pumps may be replaced with solenoid valves for pressure control. A total of up to 24 valves/syringe pumps may be implemented using such software.
(42) Flow rates between 100-500 μL/min with a sheath to cell flow fluid viscosity ratio of approximately 3:1 were investigated. This ratio of fluid viscosities was selected after numerous tests. The cell flow was simulated using deionised (DI) water while the sheath flow used a food colour dye that was significantly more viscous. The coloured dye is diluted with DI water until it is approximately three times more viscous than DI water alone. The viscosities were measured using a rheometer.
(43)
(44) From
(45) Isolation Efficiency and Sample Recovery
(46) Using 15 μm polystyrene beads to simulate cells, the effects of particle concentration introduced into the system at various inlet flow rates was investigated. This allowed the processing time required for samples of varying initial conditions to be gauged and to determine if pre-preparation of the sample (dilution or sample concentration) is required prior to loading onto the device. An optimal input concentration range will allow regular passage of single cells within tolerable time intervals. Conversely, if the concentration is too high, this may result in large losses of input cells because there is a small lag time before the cell flow can be stopped when all the cell chambers are occupied. However, a low concentration will result in a long waiting time before the chambers are completely filled and this will lengthen the processing time.
(47)
(48) In the currently depicted device, flow conditions of 1:5 for cell to sheath flow rates were used with varied total flow rates of from 100 to 400 μL/min. The time taken to occupy all 10 of the cell chambers were noted and averaged based upon five independent runs. The faster it takes to fill the chambers will enhance the throughput of the system.
(49)
(50) As mentioned in this experimental section, polystyrene beads were used to simulate cells.